TABLE 2.

Solution-phase binding affinities for dKAA

GlycopeptideKA (M−1)a determined by:
ACEESI-MS
Vancomycin(5.2 ± 0.6) × 105(13.5 ± 0.3) × 105
Telavancin(0.96 ± .03) × 105(3.2 ± 0.4) × 105
THRX-881620NDb(0.13 ± 0.006) × 105
  • a Values shown are means ± standard deviations of data from three separate experiments.

  • b ND, not determinable.